Sean E. Collins, MD, MS

Gilead Sciences, Inc., Foster City, CA, USA

Disclosure(s): Gilead Sciences, Inc: Employee

Poster(s):

• (P-365) Pooled safety and tolerability of twice-yearly lenacapavir with teropavimab and zinlirvimab for HIV-1 treatment
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-1248) Phase 2 Pharmacokinetics and Anti-Drug Antibody Results of the Investigational Twice-Yearly HIV-1 Treatment Regimen Lenacapavir, Teropavimab, and Zinlirvimab
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET